Drug pricing regulator National Pharmaceutical Pricing Authority (NPPA) has fixed ceiling prices of 67 scheduled formulations of Schedule-I under Drugs (Price Control) Order, 2013 as per order dated July 28, 2017.

Name of the scheduled formulation for which ceiling prices have been notified under Schedule-I of Drugs (Prices Control) Order, 2013 are a Trioxide, betamethasone, zinc sulphate, levothyroxine, phenylephrine, dinoprostone, 6 - mercaptopurine, esmolol, antitetanus human immunoglobin, vinblastine sulphate, atropine, coagulation factor VIII, ethambutol, homatropine, human normal immunoglobulin, abacavir (A) + lamivudine (B), atazanavir (A) + ritonavir (B), capecitabine, lamivudine (A) + nevirapine (B) + stavudine (C),lamivudine (A) + zidovudine (B), lopinavir (A) + ritonavir (B), methylprednisolone, nevirapine, rituximab, stavudine (A) + lamivudine (B), zidovudine (A) + lamivudine (B) + nevirapine (C), ranitidine, nitrofurantoin, amlodipine, azithromycin, cefixime, amoxicillin (A) + clavulanic acid (B), levofloxacin, ciprofloxacin and ringer lactate.

It has also fixed retail prices of 7 formulations under Drugs (Prices Control) Order, 2013 which are fusidic acid + mometasone furoate (Bactafuz -M Cream), rosuvastatin + aspirin (Rozucor Asp 20), metformin HCl + voglibose (Voglitor MF Forte 0.2), metformin HCl +voglibose (Voglitor MF Forte 0.3), metformin HCl + glimepiride + voglibose (TriVoglitor Forte 1) and ceftriaxone + sulbactam injection.  

The concerned manufacturers of these formulations shall furnish quarterly return to the NPPA, in respect of production/import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturers in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and/or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

In case the retail price of any of the formulations is not complied with, as per instant price notification and notes specified, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

Consequent to the issue of retail price of the formulations as specified in this notification, the price order(s) if any, issued for concerned manufacturer/marketeer prior to said date of notification, stand(s) superseded.